Interpharma Pty Ltd v Commissioner of Patents

The case of Interpharma Pty Ltd v Commissioner of Patents involved a dispute over the validity and infringement of patents related to gemcitabine hydrochloride, a pharmaceutical compound. Interpharma, the cross-claimant, alleged that the respondent, Health Care Direct Pty Ltd, was infringing on its patents through the production and distribution of the pharmaceutical product EBEGEMCIT. Interpharma sought interlocutory injunctions to prevent Health Care Direct from marketing EBEGEMCIT in Australia and from including it in the Pharmaceutical Benefits Scheme (PBS). The urgency of the application was due to the impending release of the PBS list, necessitating an application for withdrawal by a specific date to be effective.

The primary legal issues before the court were whether Health Care Direct's production and distribution of EBEGEMCIT infringed on Interpharma's patents and whether an interlocutory injunction should be granted to restrain Health Care Direct from marketing the product. The court had to consider the validity of Interpharma's patents, the nature of the alleged infringement, and the potential impact of the injunction on Health Care Direct's operations and the PBS listing process. The court also needed to balance the urgency of the situation with the need for a fair hearing of the merits of the case.

In its decision, the court found that Interpharma had established a serious question to be tried regarding the validity of the patents in question. The court concluded that the cross-claimant had made out a prima facie case of patent infringement and that an interlocutory injunction was warranted. The court emphasised the need for Health Care Direct to withdraw its application for the inclusion of EBEGEMCIT in the PBS to avoid any practical effect, given the administrative timeline for PBS updates. The court granted the relief sought by Interpharma, including an injunction against the marketing of EBEGEMCIT and a requirement for Health Care Direct to withdraw its PBS application. The court also set out a detailed timetable for the discovery process and the trial, reserving costs for later determination.

The court's final orders included restraining Health Care Direct from marketing and distributing EBEGEMCIT, requiring the withdrawal of the PBS application, and establishing a timeline for document discovery and trial preparation. The court mandated specific dates for the filing and serving of documents and affidavits, and set a trial date for June 2009, with an estimated duration of 10 days. The parties were granted liberty to apply for further orders as necessary.